Alterations of NMDA receptor binding in various brain regions among 6-hydroxydopamine-induced Parkinsonian rats

International Journal of Neuroscience

Volumn 124, Issue 6, 2014, Pages 457-465

  Wang, Qing ^a,b   Li, Jin ^a   Wei, Xiaobo ^a   Liao, Jinchi ^a   Xu, Yunqi ^a   Lu, Tingting ^a   Qin, Bing ^a   Xie, Junqiang ^a   Deng, Chao ^b   Huang, Xufeng ^b  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

MK 801; Cognition; NMDA receptors; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE; ADRENERGIC RECEPTOR STIMULATING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN DAMAGE; CAUDATE NUCLEUS; CINGULATE GYRUS; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CORTICAL AMYGDALA; DISEASE MODEL; DOPAMINERGIC NERVE CELL; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; INSULA; MALE; MEDIAL FOREBRAIN BUNDLE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PREFRONTAL CORTEX; PROTEIN LOCALIZATION; PUTAMEN; PYRIFORM CORTEX; RAT; RECEPTOR BINDING; SUBSTANTIA NIGRA PARS COMPACTA; THALAMUS; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ADRENERGIC AGENTS; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; MALE; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84899918109     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2013.853058     Document Type: Article

References (61)

1. Jacobs SA, Tsien JZ. Genetic overexpression of NR2B subunit enhances social recognition memory for different strains and species. PLoS One 2012;7(4):e36387.
2. Foster TC. Dissecting the age-related decline on spatial learning and memory tasks in rodent models: N-methyl-D-Aspartate receptors and voltage-dependent Ca2 +channels in senescent synaptic plasticity. Prog Neurobiol 2012;96(3):283-303.
3. Shi L, Adams MM, Linville MC, et al. Caloric restriction eliminates the aging-related decline in NMDA and AMPA receptor subunits in the rat hippocampus and induces homeostasis. Exp Neurol 2007;206(1):70-9.
4. Janssen WG, Vissavajjhala P, Andrews G, et al. Cellular and synaptic distribution of NR2A and NR2B in macaque monkey and rat hippocampus as visualized with subunit-specifc monoclonal antibodies. Exp Neurol 2005;191(Suppl 1):S28-44.
5. Li XB, Yang ZX, Yang L, et al. Neuroprotective effects of fax lignan against NMDA-induced neurotoxicity in vitro. CNS Neurosci Ther 2012;18(11):927-33.
6. Cevikbas F, Steinhoff M, Ikoma A. Role of spinal neurotransmitter receptors in itch: new insights into therapies and drug development. CNS Neurosci Ther 2011;17(6):742-9.
7. Wang Q, Zengin A, Deng C, Li Y, Newell KA, et al. High dose of simvastatin induces hyperlocomotive and anxiolytic-like activities: The association with the up-regulation of NMDA receptor binding in the rat brain. Exp Neurol 2009;216(1):132-8.
8. Adams MM, Shi L, Linville MC, et al. Caloric restriction and age affect synaptic proteins in hippocampal CA3 and spatial learning ability. Exp Neurol 2008;211(1):141-9.
9. Proctor DT, Coulson EJ, Dodd PR. Post-synaptic scaffolding protein interactions with glutamate receptors in synap-tic dysfunction and Alzheimer's disease. Prog Neurobiol 2011;93(4):509-21.
10. Huang YH, Ishikawa M, Lee BR, et al. Searching for presy-naptic NMDA receptors in the nucleus accumbens. J Neurosci 2011;31(50):18453-63.
11. Zhao MG, Toyoda H, Lee YS, et al. Roles of NMDA NR2B subtype receptor in prefrontal long-term potentiation and contextual fear memory. Neuron 2005;47(6):859-72.
12. Kang SJ, Liu MG, Chen T, et al. Plasticity of metabotropic glutamate receptor-dependent long-term depression in the anterior cingulate cortex after amputation. J Neurosci 2012; 32(33):11318-29.
13. Nishi A, Watanabe Y, Higashi H, et al. Glutamate regulation of DARPP-32 phosphorylation in neostriatal neurons involves activation of multiple signaling cascades. Proc Natl Acad Sci U S A 2005;102(4):1199-204.
14. Xu Y, Yan J, Zhou P, et al. Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 2012;97(1):1-13.
15. Chen WF, Chang H, Wong CS, et al. Impaired expression of postsynaptic density proteins in the hippocampal CA1 region of rats following perinatal hypoxia. Exp Neurol 2007;204(1):400-10.
16. Hussain N, Flumerfelt BA, Rajakumar N. Glutamatergic regulation of long-term grafts of fetal lateral ganglionic eminence in a rat model of Huntington's disease. Neurobiol Dis 2004;15(3):648-53.
17. Hauber W. Involvement of basal ganglia transmitter systems in movement initiation. Prog Neurobiol 1998;56(5):507-40.
18. Fabbrini G, Brotchie JM, Grandas F, et al. Levodopa-induced dyskinesias. Mov Disord 2007;22(10):1379-89.
19. Hallett PJ, Spoelgen R, Hyman BT, et al. Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit traffcking. J Neurosci 2006;26(17):4690-700.
20. Hallett PJ, Standaert DG. Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol Ther 2004;102(2):155-74.
21. Errico F, Bonito-Oliva A, Bagetta V, et al. Higher free D-Aspartate and N-methyl-D-Aspartate levels prevent striatal de-potentiation and anticipate L-DOPA-induced dyskinesia. Exp Neurol 2011;232(2):240-250.
22. Lavoute C, Weiss M, Rostain JC. Alterations in nigral NMDA and GABAA receptor control of the striatal dopamine level after repetitive exposures to nitrogen narcosis. Exp Neurol 2008;212(1):63-70.
23. Rouillon C, Abraini JH, David HN. Prefrontal cortex and basolateral amygdala modulation of dopamine-mediated locomotion in the nucleus accumbens core. Exp Neurol 2008;212(1):213-7.
24. Martella G, Platania P, Vita D, et al. Enhanced sensitivity to group II mGlu receptor activation at corticostriatal synapses in mice lacking the familial Parkinsonism-linked genes PINK1 or Parkin. Exp Neurol 2009;215(2):388-96.
25. Lester DB, Rogers TD, Blaha CD. Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 2010;16(3):137-62.
26. Li Y, Huang XF, Deng C, et al. Alterations in 5-HT2A receptor binding in various brain regions among 6-hydroxydopamine-induced Parkinsonian rats. Synapse 2010;64(3):224-30.
27. Wang Q, Wang PH, McLachlan C, Wong PT. Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats. Brain Res 2005;1045(1-2):229-33.
28. Warre R, Thiele S, Talwar S, et al. Altered function of glu-tamatergic cortico-striatal synapses causes output pathway abnormalities in a chronic model of Parkinsonism. Neurobiol Dis 2011;41(3):591-604.
29. Löschmann PA, De Groote C, Smith L, et al. Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specifc NMDA receptor antagonist, in animal models of Parkinson's disease. Exp Neurol 2004;187(1):86-93.
30. Anastasia A, de Erausquin GA, Wojnacki J, Mascó DH. Protection of dopaminergic neurons by electroconvulsive shock in an animal model of Parkinson's disease. J Neurochem 2007;103(4):1542-52.
31. Yan J, Xu Y, Zhu C, et al. Simvastatin prevents dopaminer-gic neurodegeneration in experimental Parkinsonian models: the association with anti-infammatory responses. PLoS One 2011;6(6):e20945.
32. Howard-Jones N. A CIOMS ethical code for animal experimentation. WHO Chron 1985;39:51-6.
33. Yuan H, Sarre S, Ebinger G, Michotte Y. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. J Neurosci Methods 2005;144(1):35-45.
34. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. San Diego: Academic Press; 1997.
35. Aznavour N, Cendres-Bozzi C, Lemoine L, et al. MPTP animal model of Parkinsonism: dopamine cell death or only tyrosine hy-droxylase impairment? A study using PET imaging, autoradio-graphy, and immunohistochemistry in the cat. CNS Neurosci Ther 2012;18(11):934-41.
36. Betarbet R, Poisik O, Sherer TB, Greenamyre JT. Differential expression and ser897 phosphorylation of striatal N-methyl-D-Aspartate receptor subunit NR1 in animal models of Parkinson's disease. Exp Neurol 2004;187(1):76-85.
37. Dunah AW, Wang Y, Yasuda RP, et al. Alterations in subunit expression, composition, and phosphorylation of stri-Atal N-methyl-D-Aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol Pharmacol 2000;57(2):342-52.
38. Greenamyre JT, O'Brien CF. N-methyl-D-Aspartate antagonists in the treatment of Parkinson's disease. Arch Neurol 1991;48(9):977-81.
39. Starr MS. Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse 1995;19(4):264-293.
40. Vernon AC, Zbarsky V, Datla KP, et al. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo. J Neurochem 2007;103(3):1075-91.
41. Jellinger KA. The pathology of Parkinson's disease. Adv Neurol 2001;86:55-72.
42. Sgambato-Faure V, Cenci MA. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. Prog Neurobiol 2012;96(1):69-86.
43. Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials. Mov Disord 2012;28(2):131-44.
44. Meshul CK, Allen C. Haloperidol reverses the changes in stri-Atal glutamatergic immunolabeling following a 6-OHDA lesion. Synapse 2000;36(2):129-42.
45. Maccarrone M, Gubellini P, Bari M, et al. Levodopa treatment reverses endocannabinoid system abnormalities in experimental Parkinsonism. J Neurochem 2003;85(4):1018-1025.
46. He L, Di Monte DA, Langston JW, Quik M. Autoradiographic analysis of N-methyl-D-Aspartate receptor binding in monkey brain: effects of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahy-dropyridine and levodopa treatment. Neuroscience 2000;99(4): 697-704.
47. Fox SH, Brotchie JM, Lang AE. Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurol 2008;7(10):927-938.
48. Alves G, Forsaa EB, Pedersen KF, et al. Epidemiology of Parkinson's disease. J Neurol 2008;255(Suppl 5):18-32.
49. Tadaiesky MT, Dombrowski PA, Figueiredo CP, et al. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 2008;156(4):830-40.
50. Karlsgodt KH, Robleto K, Trantham-Davidson H, et al. Reduced dysbindin expression mediates N-methyl-D-Aspartate receptor hypofunction and impaired working memory performance. Biol Psychiatry 2011;69(1):28-34.
51. Corcoran KA, Donnan MD, Tronson NC, et al. NMDA receptors in retrosplenial cortex are necessary for retrieval of recent and remote context fear memory. J Neurosci 2011;31(32):11655-9.
52. Laurie DJ, Seeburg PH. Ligand affnities at recombinant N-methyl-D-Aspartate receptors depend on subunit composition. Eur J Pharmacol 1994;268:335-45.
53. Zhu G, Chen Y, Huang Y, et al. MPTP-meditated hippocam-pal dopamine deprivation modulates synaptic transmission and activity-dependent synaptic plasticity. Toxicol Appl Pharmacol 2011;254(3):332-41.
54. Olivares D, Deshpande VK, Shi Y, et al. N-methyl D-Aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease. Curr Alzheimer Res 2012;9(6):746-58.
55. Hsieh MH, Gu SL, Ho SC, et al. Effects of MK-801 on recognition and neurodegeneration in an MPTP-induced Parkinson's rat model. Behav Brain Res 2012;229(1):41-7.
56. May-Simera H, Levin ED. NMDA systems in the amygdala and piriform cortex and nicotinic effects on memory function. Brain Res Cogn Brain Res 2003;17(2):475-83.
57. Shi L, Adams MM, Long A, et al. Spatial learning and memory defcits after whole-brain irradiation are associated with changes in NMDA receptor subunits in the hippocampus. Radiat Res 2006;166(6):892-9.
58. Tang J, Strafella AP. The frontostriatal circuitry and behavioral complications in PD. Parkinsonism Relat Disord Suppl 2012;1:S104-6.
59. Bartels AL, Leenders KL. Brain imaging in patients with freezing of gait. Mov Disord 2008;23(Suppl 2):S461-7.
60. Tamaru F. Disturbances in higher function in Parkinson's disease. Eur Neurol 1997;38:33-6.
61. Aarsland D, Brønnick K, Larsen JP, et al. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest Study. Neurology 2009;72(13):1121-6.